VLA1553 (Pediatric)
Chikungunya (prevention) in pediatric population
Phase 3Active
Key Facts
About Valneva SE
Valneva SE is a publicly traded biotech company dedicated to providing life-saving vaccines against infectious diseases. Its strategy combines commercial revenue from its travel and endemic vaccines with a late-stage pipeline targeting Lyme disease and other threats. The company leverages its proprietary vaccine platform technology and in-house manufacturing to control the entire value chain, positioning itself as a key player in the global response to emerging infectious diseases and neglected travel health markets.
View full company profile